Alaunos Therapeutics (TCRT) Enterprise Value (2009 - 2026)

Alaunos Therapeutics has reported Enterprise Value for 18 years, with the latest figure at -$354000.0 in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 10.97% year-over-year to -$354000.0; the trailing twelve-month figure through Mar 2026 stood at -$354000.0 (down 10.97% YoY), and the FY2025 full-year result was -$1.4 million, down 26.95% from the prior year.
• Enterprise Value for Q1 2026 stood at -$354000.0, up from -$1.4 million in the prior quarter.
• The five-year high for Enterprise Value was -$319000.0 in Q1 2025, with the low at -$68.3 million in Q1 2022.
• Historically, Enterprise Value has averaged -$19.0 million across 5 years, with a median of -$4.1 million in 2024.
• The largest YoY upside for Enterprise Value was 92.3% in 2025 against a maximum downside of 26.95% in 2025.
• Alaunos Therapeutics' Enterprise Value stood at -$53.0 million in 2022, then surged by 88.56% to -$6.1 million in 2023, then surged by 82.0% to -$1.1 million in 2024, then retreated by 26.95% to -$1.4 million in 2025, then soared by 74.44% to -$354000.0 in 2026.
• The last three Enterprise Value figures came in at -$354000.0 (Q1 2026), -$1.4 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.